MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

MDS Virtual Congress 2021

September 17-22, 2021. Virtual Congress. www.mdscongress.org

View by Title View Categories
Jump to:  View All • a b c d e f g h i j k l m n o p q r [s] t u v w x y z
  • Safety and effectiveness of unilateral MRgFUS thalamotomy in elderly patients with essential and parkinsonian tremor

    J. Carte-García, A. Gorospe, I. Avilés, A. Martín-Bastida, O. Parras, A. Arcadi, M. Fernández, L. González, J. Guridi, MC. Rodríguez-Oroz (Pamplona/iruña, Spain)

  • Safety and efficacy of unilateral subthalamotomy by magnetic resonance guided focused ultrasound (MRgFUS) in asymmetrical Parkinson’s disease (PD).

    L. Armengou Garcia, I. Avilés Olmos, MA. Gorospe Osinalde, M. Fernández Martínez, A. Arcadi, A. Martin Bastida, G. Montoya Murillo, C. Arrondo Elizarran, P. Manrique Lara, L. González Quarante, J. Guridi Legarra, MC. Rodriguez Oroz (Pamplona, Spain)

  • Safety and Tolerability of a Ketone Supplement in Parkinson’s Disease

    M. Beke, P. Mackie, E. Klann, C. Rusch, A. Gurrala, S. Chua, E. Ince, L. Almeida, A. Ramirez-Zamora (Gainesville, USA)

  • Safety of MRI performed with leads-only or fully implanted DBS system

    J. Wilden, C. Torres Diaz, S. Groppa, D. Gaudin, E. Hargreaves, D. Vansickle, P. Slotty, A. Gharabaghi, E. Jiltsova, S. Ojemann, J. Aldred, S. Redding, D. Weiss, F. Defresne, E. Karst, B. Cheeran, R. Gross (Shrevport, USA)

  • Safety, tolerability and CNS effects after single and multiple doses of β-agonists in healthy volunteers and patients with Parkinson’s disease

    P. Eijsvogel, S. Prins, L. Moss, L. Borghans, B. van Kraaij, E. van Brummelen, E. Klaassen, R. Martin, E. Bautista, A. Ford, GJ. Groeneveld, G. Vargas (Leiden, Netherlands)

  • Safinamide Improves Mood in Parkinson´s Disease. Results from the SAFINONMOTOR Study.

    C. Labandeira, MG. Alonso Losada, R. Yáñez Baña, I. Cimas Hernando, I. Cabo López, JM. Paz González, MJ. González Palmás, C. Martínez Miró, D. Santos García (Vigo, Spain)

  • Safinamide Improves Pain in Parkinson´s Disease. Results from the SAFINONMOTOR Study.

    R. Yáñez, C. Labandeira, M. Cimas Hernando, I. Cabo, J. Paz González, M. Alonso Losada, M. González Palmás, C. Martínez, D. Santos García (Ourense, Spain)

  • Safinamide Improves Sleep and Daytime Sleepiness in Parkinson´s Disease. Results from the SAFINONMOTOR Study

    I. Cabo López, C. Labandeira Guerra, R. Yáñez Baña, MI. Cimas Hernando, JM. Paz González, MG. Alonso Losada, MJ. González Palmás, C. Martínez Miró, D. Santos García (Pontevedra, Spain)

  • SARS CoV2 in older patients with Parkinson’s.

    M. Khwaja, T. Nanayakkara, G. Pun, M. Todd, A. Chatterjee, N. Butt, N. Virgincar (Reading, United Kingdom)

  • SARS-CoV-2 Encephalopathy Presenting as Opsoclonus Myoclonus Syndrome Successfully Treated with IV Immunoglobulins

    M. Salgado, I. Hacker, A. Alport, J. Ma (Brooklyn, USA)

  • Satisfaction of Parkinson patients, caregivers and clinicians after STN-DBS and its predictors

    A. Konitsioti, N. Schnalke, M. Kurz, L. Astrakas, W. Polanski, S. Sobottka, B. Falkenburger, H. Reichmann, L. Klingelhöfer (Cologne, Germany)

  • Satisfaction Survey on a Parkinson’s Holter, a Medical Device for the Monitoring of Motor Symptoms

    DRM. Rodriguez-Martin, CPL. Perez-Lopez, MP. Pié, JC. Calvet, ACM. Català, ARM. Rodríguez-Molinero, JCM. Cabestany (Cornella Llobregat, Spain)

  • SB-0107, a drug repurposing opportunity identified through machine learning, shows the potential to treat Parkinson’s disease motor disability and levodopa-induced dyskinesia in rat and primate models

    A. Bordbar, K. Merchant, D. Weiner, M. Hill, J. Brotchie, T. Johnston, I. Famili (San Diego, USA)

  • Secondary endpoints of a randomized, placebo-Controlled Pilot Study to evaluate the safety of lyophilized PRIM-DJ2727 in Parkinson’s disease

    J. Suescun, M. Schiess, Z. Jiang, V. Thyne, T. Iqbal, N. Utay, M. Newmark, A. Dupont, A. Alexander, H. Dupont (Houston, USA)

  • Self perceived impact of the SARS-COV 2 pandemic on motor, non motor and affective symptoms in Parkinson’s disease and parkinsonisms.

    A. Ranghetti, V. Cereda, R. Maestri, C. Siri, M. Canesi (Gravedona Ed Uniti, Italy)

  • SELF-REHABILITATION WITH CONNECTED INSOLES IN PARKINSON’S DISEASE : RESULTS OF A PILOT STUDY.

    A. Laplanche, S. Ferre, D. Jacobs, L. Farid, A. Post, C. Moreau, B. Degos, G. Baille (Paris, France)

  • Sensory Tricks Modulate Corticocortical and Corticomuscular Connectivity in Cervical Dystonia

    S. Cho, S. Lee, H. Shin, M. Hallett (Bethesda, USA)

  • Serial DaT-SPECT imaging in asymptomatic carriers of LRRK2 G2019S mutation: 8-years follow-up

    A. Sánchez Rodríguez, I. Martínez Rodríguez, M. Sierra, P. Sánchez Juan, I. González Aramburu, M. Rivera Sánchez, J. Andrés Pacheco, A. Gutiérrez-González, O. Cuenca-Vera, J. Madera, A. García-Hernández, J. Infante (Santander, Spain)

  • Serial olfactory testing for the diagnosis of prodromal Parkinson disease in the Parkinson Associated Risk Syndrome (PARS) study

    P. Vaswani, J. Morley, D. Jennings, A. Siderowf, K. Marek, P. Investigators (Philadelpiha, USA)

  • Serum uric acid as a putative biomarker in Prodromal Parkinson’s disease: Longitudinal data from the PPMI study.

    C. Koros, A-M. Simitsi, N. Papagiannakis, A. Bougea, A. Prentakis, D. Papadimitriou, I. Pachi, R. Antonelou, E. Angelopoulou, E. Efthymiopoulou, I. Beratis, M. Bozi, S. Papageorgiou, A. Bonakis, M. Stamelou, L. Stefanis (Athens, Greece)

  • Sex differences in brain and cognition in de novo PD patients

    J. Oltra, C. Uribe, A. Campabadal, A. Inguanzo, G. Monté-Rubio, M. Marti, Y. Compta, F. Valldeoriola, C. Junque, B. Segura (Barcelona, Spain)

  • Sex-Specific APOE ε4 Association with Cognition in Lewy Body Dementia

    E. Bayram, S. Scholz, I. Litvan (La Jolla, USA)

  • Sex-specific associations between care partner burden and activities of daily living in Parkinson’s disease

    R. Gandhi, D. Schiehser, N. Whiteley, V. Filoteo, S. Lessig, I. Litvan, E. Bayram (La Jolla, USA)

  • Sex-Specific White Matter Correlates of Neuropsychological Measures in Parkinson’s disease with Mild Cognitive Impairment

    V. Mishra, K. Sreenivasan, D. Cordes, A. Ritter, Z. Mari, J. Caldwell (Las Vegas, USA)

  • Sexual divergencies in monoaminergic projections in Parkinson’s disease: a 123I-FP-CIT SPECT study

    S. Masciocchi, A. Pilotto, E. Premi, M. Toffali, A. Imarisio, B. Paghera, A. Padovani (Brescia, Italy)

  • Sexual dysfunction in female patients with Multiple System Atrophy

    C. Raccagni, E. Indelicato, V. Sidoroff, M. Daniaux, A. Bader, B. Toth, L. Jelisejevas, A. Fanciulli, F. Leys, S. Eschlboeck, C. Kaindlstorfer, S. Boesch, G. Wenning (Innsbruck, Austria)

  • Shank range of motion as a measure of gait impairment in TUG test

    G. Rigas, N. Kostikis, N. Tachos, K. Tsamis, M. Tsiknakis, S. Konitsiotis, D. Fotiadis (Ioannina, Greece)

  • Shannon entropy: a novel tool for assessing pentagon drawing in Parkinson’s disease

    L. Brabenec, P. Klobusiakova, J. Mekyska, I. Rektorova (Brno, Czech Republic)

  • SHBG, and possibly testosterone, are associated with the risk for Parkinson’s disease among women: a Mendelian randomization approach

    C. Kusters, K. Paul, A. Duarte Folle, A. Keener, J. Bronstein, L. Bertram, J. Hansen, S. Horvath, J. Sinsheimer, C. Lill, B. Ritz (Los Angeles, USA)

  • Should Amantadine DR/ER Be Considered Prior to Device-Aided Therapies for Parkinson’s Disease?

    R. Hauser, S. Goud, A. Formella (Tampa, USA)

  • Significant increase of new pediatric functional movement disorders during the COVID-19 global pandemic

    K. Mackenzie, J. O'Malley (Palo Alto, USA)

  • Silencing of hypoxia-inducible factor 1 alpha provokes a neuroprotective response in a SH-SY5Y model of Parkinson’s Disease.

    S. Acharya, A. Lumley, C. Mebarki, V. Stopa, M. Vausort, Y. Devaux (Strassen, Luxembourg)

  • Single-Trajectory Multiple-Target Deep Brain Stimulation to treat Mobility and Cognition in Parkinson’s Disease: a Double-Blind, Randomized, Cross-Over Pilot Study

    S. Sasikumar, M. Cohn, I. Harmsen, A. Loh, S. Kalia, A. Lozano, A. Fasano (Toronto, Canada)

  • Sleep assessment with Fitbit4 in Parkinson’s disease

    S. Diaconu, L. Ungureanu, R. Rancz, B. Ciopleiaș, L. Irincu, I. Ivan, C. Falup-Pecurariu (Brasov, Romania)

  • Sleep disorders and future diagnosis of parkinsonism: a prospective study using the Canadian Longitudinal Study on Aging

    S. Zolfaghari, C. Yao, C. Wolfson, A. Pelletier, R. Postuma (Montreal, Canada)

  • Sleep Quality and Nutrition effects in patients with Parkinson’s Disease

    C. López Botello, A. Pérez Arzola, B. Chávez Luevanos, S. Castillo Torres, D. Martínez Roque, I. Estrada Bellmann (Monterrey, Mexico)

  • Slow Motion Analysis of Repetitive Tapping (SMART) test: measuring of bradykinesia in recently diagnosed Parkinson’s disease and idiopathic anosmia

    C. Simonet, M. Galmes, C. Lambert, R. Rees, T. Haque, J. Bestwick, A. Lees, A. Schrag, A. Noyce (London, United Kingdom)

  • Slow wave activity as a marker of levodopa induced dyskinesia

    N. Amato, S. Caverzasio, M. Caporro, P. Agazzi, C. Staedler, A. Kaelin-Lang, S. Galati (Lugano, Switzerland)

  • Slowly progressive spastic paraplegia due to rare mitochondrial dysfunction: a clinical case

    D. Silva, A. Travessa, R. Roque, L. Guedes (Lisbon, Portugal)

  • Smartphone-based mobility assessment in Parkinson’s disease: A validity study

    YQ. Chua, HW. Ho, SY. Choong, JY. Voon, ZR. Yee, ML. Tan, CL. Chung (Singapore, Singapore)

  • Smell dysfunction correlates with severity of motor deficits in H&Y stage-I early onset Parkinson’s disease

    J. Wang, R. Stanford, Q. Yang, L. Spreen, M. Wang, B. Mullen, K. Venkiteswaran, T. Subramanian (Hershey, USA)

  • Social support moderates the burden of nonmotor but not motor symptoms among patients with Parkinson’s disease

    HJ. Yang, A. Kim, BS. Park (Ulsan, Republic of Korea)

  • Sociodemographic, cognitive, and clinical factors explaining financial-arithmetic errors in Parkinson’s Disease

    H. Loenneker, S. Becker, S. Nussbaum, H-C. Nuerk, I. Liepelt-Scarfone (Tuebingen, Germany)

  • Soluble urokinase-type plasminogen activator receptor (SuPAR) in patients with Parkinson’s disease

    N. Witek, J. Joyce, J. Hawkins, Y. Liu, B. Ouyang, R. Patel, J. Borgia, J. Reiser, D. Hall (Chicago, USA)

  • Somatosensory temporal discrimination in essential tremor treated with HIFU VIM thalamotomy: tremoric and lesional effects on the STDT

    CM. Ordás Bandera, F. Alonso-Frech, R. Martínez-Fernández, M. Del álamo, JA. Obeso (Móstoles, Spain)

  • Spatiotemporal dynamics in mild cognitive impairment with Lewy bodies

    M. Lamoš, I. Morávková, D. Ondráček, M. Bočková, I. Rektorová (Brno, Czech Republic)

  • Speaking with your hands in Parkinson’s: Investigating the rate and precision of co-speech gestures

    E. Poliakoff, M. Marciniak, A. Bettis, S. Humphries (Manchester, United Kingdom)

  • Spectrum of Movement Disorders among Children with Subacute Sclerosing Panencephalitis (SSPE): A Cross-sectional Study

    D. Garg, V. Kakkar, D. Kapoor, S. Sharma, S. Mukherjee, H. Pemde (New Delhi, India)

  • Spectrum of Movement disorders and Correlation with Functional Status in Children with Cerebral Palsy

    S. Narayanaswamy, D. Garg, S. Pandey, R. Majumdar, S. Mukherjee, S. Sharma (Delhi, India)

  • SPEECH BIOMARKERS IN HEREDITARY SPASTIC PARAPLEGIA

    M. Olchik, L. Scudeiro, V. Dos Santos, A. Ayres, R. Rech, D. Burguêz, G. Machado, C. González-Salazar, M. Padovani, M. França Junior, J. Saute (Porto Alegre, Brazil)

  • SPG21 in Europe: Mutations outside the Amish community

    M. Amprosi, E. Indelicato, A. Eigentler, W. Nachbauer, S. Boesch (Innsbruck, Austria)

  • Sphingosine-1-phosphate, motor severity and progression in Parkinson’s disease (MARK-PD)

    C. Choe, C. Englisch, L. Niemann, S. Lezius, M. von Lucadou, K. Marmann, R. Böger, S. Peine, G. Daum, C. Gerloff, E. Schwedhelm (Hamburg, Germany)

  • Spinal Excitability and Plasticity in Hereditary Spastic Paraparesis: A Neurophysiological Study

    A. Zampogna, A. Guerra, F. Asci, A. Funcis, C. Celletti, F. Camerota, A. Berardelli, A. Suppa (Rome, Italy)

  • Spinal myoclonus in secondary progressive multiple sclerosis

    N. Raisa, B. Munir, S. Rianawati (Malang, Indonesia)

  • Spinal orthosis in antecollis and PISA syndrome in Parkinson.

    N. Batasuk, P. Ruthiraphong (Bangkok, Thailand)

  • Spinocerebellar ataxia (SCA) type 2 and type 8: a tale of two repeat expansions in a single patient

    J. Frey, T. Tholanikunnel, L. Kugelmann, M. Burns, S. Subramony (Gainesville, USA)

  • Spread to a third body site in patients with segmental/multifocal idiopathic adult-onset dystonia

    T. Ercoli, R. Erro, G. Fabbrini, R. Pellicciari, P. Girlanda, C. Terranova, L. Avanzino, F. Di Biasio, P. Barone, M. Esposito, G. de Joanna, R. Eleopra, F. Bono, L. Manzo, AR. Bentivoglio, M. Petracca, MM. Mascia, A. Albanese, A. Castagna, R. Ceravolo, MC. Altavista, C. Scaglione, L. Magistrelli, M. Zibetti, L. Bertolasi, M. Coletti Moja, MS. Cotelli, G. Cossu, B. Minafra, A. Pisani, S. Misceo, N. Modugno, M. Romano, D. Cassano, A. Berardelli, G. Defazio (Cagliari, Italy)

  • SRY as a potential therapeutic target for men with Parkinson’s Disease

    V. Harley (Clayton, Australia)

  • Stabilization of overall quality of life via interdisciplinary home visits among individuals with advanced PD

    J. Fleisher, M. Levin, K. Woo, S. Hess, F. Akram, B. Ouyang, D. Hall, J. Chodosh (Chicago, USA)

  • STATINS IN PARKINSON’S DISEASE: INFLUENCE ON MOTOR PROGRESSION

    G. Palermo, S. Giannoni, M. Giuntini, E. Belli, D. Frosini, G. Siciliano, R. Ceravolo (Pisa, Italy)

  • Statistical methods for dealing with missing data in longitudinal studies with application to Parkinson’s disease cognition research

    P. Zhang, S. Xie (Philadelphia, USA)

  • Stereotypy after bilateral opercular infarctions.

    H. Wang, K. Mongeon-Wahlen, F. Ali (Mankato, USA)

  • Stiff Person Syndrome Presenting with Dystonia

    F. Gao (Honolulu, USA)

  • Stiff-person syndrome – a 15-year review at a tertiary hospital

    R. Rodrigues, L. Sousa, R. Samões, G. Cação, J. Chaves, M. Cardoso, J. Barros, E. Santos, J. Damásio (Santa Maria Feira, Portugal)

  • Strategies for Social Prescribing: Combating Loneliness in Parkinson’s Disease

    I. Subramanian, J. Farahnik, L. Mischley (Los Angeles, USA)

  • STRATEGIES OF PREVENTION, TREATMENT AND FOLLOW UP THROUGH TELEHEALTH FOR INDIVIDUALS WITH PARKINSON DISEASE DURING COVID-19 PANDEMIC: STUDY OF PROTOCOL

    N. Barboza, M. Terra, M. Bueno, H. Araújo, R. de Souza, T. da Silva, A. Miri, R. Volpe, L. Pereira, P. da Silva, L. Dal Molin, S. Smaili (Londrina, Brazil)

  • Stratified genome-wide association study revealed novel interactions for the top hit Parkinson’s disease loci.

    K. Senkevich, S. Bandres-Ciga, E. Yu, L. Krohn, Z. Gan-Or (Montreal, Canada)

  • Striatal dopamine transporter imaging in Parkinson’s disease drug-naïve patients: focus on sexual dysfunction

    E. Contaldi, L. Magistrelli, I. Campini, C. Comi (Novara, Italy)

  • Striatal dopaminergic loss in early clinically unilateral Parkinson’s disease: a systematic review

    N. Heng, N. Malek, M. Lawton, K. Grosset, Y. Ben-Shlomo, D. Grosset (Glasgow, United Kingdom)

  • Structural and functional cerebellar alterations in Parkinson’s disease with postural instability and gait disorders

    A. Gardoni, E. Sarasso, S. Basaia, MA. Volonté, M. Filippi, F. Agosta (Milan, Italy)

  • Study Design to Assess the Effect of Opicapone on Levodopa PK at Different Levodopa-Optimized Treatment Regimens in Parkinson’s Disease Patients

    J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

  • Studying of the correlation between the severity of ischemic stroke and the severity of post-stroke spasticity in the early recovery period

    S. Rudenko, N. Nekrasova (Kharkiv, Ukraine)

  • Subacute cerebellar degeneration and Holmes tremor secondary to paraneoplastic non-Hodgkin’s lymphoma

    J. Frey, J. Toledo, A. Ramirez-Zamora, I. Malaty (Gainesville, USA)

  • Subclinical inflammation and Parkinson’s disease

    G. Pagano (Basel, Switzerland)

  • Subcortical spectral perturbations during foot movements in PD patients with and without dystonia

    A. Nakhmani, C. Hurt, D. Kuhman, M. Wade, J. Olson, B. Guthrie, H. Walker (Birmingham, USA)

  • Subcutaneous Levodopa Infusion for Parkinson’s disease Patients with Motor Fluctuations: Open-Label Efficacy Outcomes from the BeyoND study

    W. Poewe, F. Stocchi, L. Adar, R. Case, T. Yardeni, A. Espay (Innsbruck, Austria)

  • Subjective cognitive complaints assessed with the cognitive domain of the Non-Motor Symptoms Scale predict longitudinal cognitive trajectory in people with Parkinson’s disease with normal cognition

    L. Batzu, DJ. van Wamelen, D. Urso, V. Leta, A. Podlewska, K. Rukavina, J. Staunton, YM. Wan, A. Rizos, K. Ray Chaudhuri (London, United Kingdom)

  • Substantia nigra pars compacta integrity is associated with DRT-related motor symptom improvement in Parkinson’s disease

    S. Atkinson, R. Seo, D. Peterson, B. Cholerton, SC. Hu, T. Montine, T. Grabowski, C. Zabetian, S. Rane (Seattle, USA)

  • Subthalamic nucleus deep brain stimulation implant hemisphere differentially changes verbal fluency in patients with Parkinson disease

    V. Del Bene, D. Marotta, R. Martin, C. Gonzalez, J. Bentley, B. Guthrie, S. Black, M. Nelson, H. Walker (Birmingham, USA)

  • Successful bilateral pallidal stimulation in a young adult with DYT-27: A case report

    M. Nguyen, S. Khandhar, M. Anderson, P. Pezeshkian, M. Sedrak, R. Ceponiene (Elk Grove, USA)

  • Successful external defibrillation in a patient with bilateral deep brain stimulation

    J. Sadasivan, J. Wong, T. Stiep, A. Patterson, L. Almeida (Gainesville, USA)

  • Supervised, home-based, real-time videoconferencing telerehabilitation preserves perception of some clinical aspects in people with Parkinson’s disease: preliminary data of a retrospective study

    E. Tardelli, E. Okamoto, F. Almeida, AM. Neto, E. Barbosa, C. Batista (São Paulo, Brazil)

  • Surface EMG signal features of Parkinson’s disease may support interpretation of home-based measurement data

    S. Rissanen, M. Koivu, P. Hartikainen, A. Sinokki, P. Karjalainen, E. Pekkonen (Kuopio, Finland)

  • Surround inhibition (SI) in the human motor system during real life motor tasks.

    P. Kassavetis, T. Camacho, M. Levine, M. Hallett (Bethesda, USA)

  • Survey-Based study of marijuana used in Parkinson’s Disease patients

    R. Healy, J. Paulson, A. Deb, K. Smith (Worcester, USA)

  • Synchronous or asynchronous exercises is beneficial compared to no exercise in Brazilian people with Parkinson’s disease during COVID-19 pandemic.

    E. Tardelli, E. Okamoto, F. Tarallo, K. Tanaka, F. Santinelli, L. Simieli, E. Costa, F. Barbieri (São Paulo, Brazil)

  • Synergistic effects of short pulse and directional deep brain stimulation of the thalamic ventral intermediate area for essential tremor

    U. Hidding, M. Schaper, W. Hamel, M. Pötter-Nerger, C. Moll, C. Choe (Hamburg, Germany)

  • Syntactic and Theory of Mind difficulties in Huntington’s disease

    A. Nuzzi (Bari, Italy)

  • Systematic review of cognitive subtypes derived from data driven approaches in Parkinson’s disease

    D. Pourzinal, J. Yang, R. Lawson, K. Mcmahon, G. Byrne, N. Dissanayaka (Herston, Australia)

Jump to:  View All • a b c d e f g h i j k l m n o p q r [s] t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley